Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Breast Neoplasms 61Carcinoma, Renal Cell 39Neoplasm Metastasis 38Neoplasms 24Kidney Neoplasms 20Neuroendocrine Tumors 19Recurrence 16Prostatic Neoplasms 15Head and Neck Neoplasms 13Tuberous Sclerosis 12Triple Negative Breast Neoplasms 12Lymphoma, Mantle-Cell 11Hodgkin Disease 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma 10Colorectal Neoplasms 10Waldenstrom Macroglobulinemia 9Stomach Neoplasms 9Multiple Myeloma 9Leukemia, Lymphocytic, Chronic, B-Cell 9Glioma 9Glioblastoma 9Brain Neoplasms 9Sarcoma 8Pancreatic Neoplasms 8Melanoma 8Lymphoma, Follicular 8Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 8

Interventions

trametinib 1spartalizumab 1pembrolizumab 1lenvatinib 1dabrafenib 1Sorafenib 1Sodium Iodide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thyroid cancer, Hurthle cell × Everolimus × Clear all
NCT02143726 2026-02-11

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Active not recruiting
35 enrolled 14 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡